Chroman-2-ylmethanamine is primarily utilized in the pharmaceutical industry as a key intermediate in the synthesis of various bioactive compounds. Its structure is particularly valuable in the development of drugs targeting neurological disorders, such as antidepressants and anxiolytics, due to its ability to interact with neurotransmitter systems. Additionally, it serves as a building block in the creation of compounds with potential antioxidant properties, which can be explored for therapeutic applications in oxidative stress-related conditions. Researchers also investigate its derivatives for their potential in treating cardiovascular diseases, leveraging its unique chemical framework to enhance drug efficacy and selectivity.